Drug-Diagnostic Co-Development in Cancer

@article{Winther2012DrugDiagnosticCI,
  title={Drug-Diagnostic Co-Development in Cancer},
  author={Henrik Winther and J. J{\o}rgensen},
  journal={Pharmaceutical Medicine},
  year={2012},
  volume={24},
  pages={363-375}
}
  • Henrik Winther, J. Jørgensen
  • Published 2012
  • Medicine
  • Pharmaceutical Medicine
  • Within oncology, companion diagnostics are considered to be of important value as the efficacy rates of anticancer pharmacotherapy in many cases remain low. Both the costs and the consequences of treatment failure are significant. Drug-diagnostic combinations have been known for several decades within oncology and the preselection of patients based on the differences in their biology was practiced as early as the 1970s. In relation to the development of the first companion diagnostic (for the… CONTINUE READING
    14 Citations
    Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity.
    • 3
    • PDF

    References

    SHOWING 1-10 OF 50 REFERENCES
    Opportunities and challenges in the development of targeted therapies.
    • 31
    The role of companion diagnostics in the development and use of mutation-targeted cancer therapies
    • 124
    Personalized cancer therapy--the key to the future.
    • K. Sikora
    • Medicine, Biology
    • Pharmacogenomics
    • 2004
    • 14
    Targeted HER2 Treatment in Advanced Gastric Cancer
    • 138
    The new era of personalized medicine: 10 years later.
    • 12
    K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
    • 3,137
    • PDF
    Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
    • 9,074
    • Highly Influential
    • PDF
    Treatment options in metastatic renal carcinoma: an embarrassment of riches.
    • N. Vogelzang
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2006
    • 125
    Randomized Phase III Clinical Trial Designs for Targeted Agents
    • 87
    • PDF